Early Movers: CLWR, S, AAPL & More
Check out which companies are making headlines before the bell on Monday:
Apple - Citi has downgraded Apple shares to "neutral" from "buy," saying the recent cut in iPhone orders brings demand into question.
Enzon Pharmaceuticals - The drugmaker has retained Lazard to explore a sale of assets or the company as a whole. It's also suspended clinical development of its androgen receptor program in order to conserve capital and maximize shareholder value.
Texas Instruments - Stern Agee has downgraded the chipmaker's stock to "underperform" from "neutral," saying the company's exit from the wireless market next year could pressure revenues and profit margins. The firm also says the stock trades at a premium to its peers.
Dean Foods - Morgan Stanley has begun coverage of the food producer, rating it "overweight."
Intel, Apple, and Hewlett-Packard - An International Trade Commission judge has ruled in favor of those three technology giants in a patent case. X2Y Attenuators, a small semiconductor maker, had alleged that the three had infringed its patents. The case involved Intel chips that were used in Apple and HP computers.
Wal-Mart Stores - The retail giant has cut prices on Apple products for the holiday season, including the third-generation iPad and the iPhone 5.
American International Group - AIG is planning to raise up to $6.5 billion through a sale of shares of its remaining stake in Asian insurer AIA Group. It had sold part of AIA following the 2008 bailout of AIG in order to raise funds.
Knight Capital Group - Knight Capital is holding a board meeting this morning, amid reports from The Wall Street Journal that the two firms bidding for Knight are considering whether to raise their bids. Getco and Virtu Financial have already each offered more than $1 billion to buy the trading firm.
Sun Life Financial - Sun Life is selling its U.S. annuity business to Delaware Life Holdings for $1.35 billion.
(Read More: See CNBC's Market Insider Blog)
—By CNBC's Peter Schacknow
Questions? Comments? Email us at email@example.com